A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 May 2016
At a glance
- Drugs Panitumumab (Primary)
- Indications CNS cancer; Glioma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen
- 07 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2014 New source identified and integrated (Vanderbilty - Ingram Cancer Center - VICCPED1395).
- 06 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov.